PE20130384A1 - Derivados de benzotiazepina - Google Patents
Derivados de benzotiazepinaInfo
- Publication number
- PE20130384A1 PE20130384A1 PE2012002082A PE2012002082A PE20130384A1 PE 20130384 A1 PE20130384 A1 PE 20130384A1 PE 2012002082 A PE2012002082 A PE 2012002082A PE 2012002082 A PE2012002082 A PE 2012002082A PE 20130384 A1 PE20130384 A1 PE 20130384A1
- Authority
- PE
- Peru
- Prior art keywords
- dioxido
- methyloxy
- phenyl
- butyl
- ethyl
- Prior art date
Links
- 229940085242 benzothiazepine derivative selective calcium channel blockers with direct cardiac effects Drugs 0.000 title 1
- 150000007657 benzothiazepines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical class [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- -1 BENZOTHIAZEPINE DERIVATIVE COMPOUND Chemical class 0.000 abstract 1
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009103 reabsorption Effects 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/6541—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
SE REFIERE A UN COMPUESTO DERIVADOS DE BENZOTIAZEPINA DE FORMULA (I) DONDE R1 ES H, Br, Cl, N(CH3)2 O METOXILO; R2 ES H U OH; R3 ES ALQUILO C1-C6; R4 ES OH, SO3H, CO2H, PO3H2, ENTRE OTROS; X ES CH2, C(O) O CH=CH; Q ESTA AUSENTE O ES ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS: (a) 3-[(3R, 5R)-3-BUTIL-3-ETIL-7-(METILOXI)-1,1-DIOXIDO-5-FENIL-2,3,4,5-TETRAHIDRO-1,4-BENZOTIAZEPIN-8-IL]-N-(METIL-SULFONIL)-PROPANAMIDA, ACIDO ({3-[(3R,5R)-3-BUTIL-3-ETIL-7-(METILOXI)-1,1-DIOXIDO-5-FENIL-2,3,4,5-TETRAHIDRO-1,4-BENZOTIAZEPIN-8-IL]-PROPANOIL}-AMINO)-METAN-SULFONICO ENTRE OTROS. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN INHIBIDOR DE LA REABSORCION ILEAL DEL ACIDO BILIAR (ASTB) SIENDO UTIL EN EL TRATAMIENTO DE DIABETES MELLITUS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32821210P | 2010-04-27 | 2010-04-27 | |
| US32922510P | 2010-04-29 | 2010-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130384A1 true PE20130384A1 (es) | 2013-04-04 |
Family
ID=44861895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002082A PE20130384A1 (es) | 2010-04-27 | 2011-04-27 | Derivados de benzotiazepina |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US9040518B2 (es) |
| EP (1) | EP2563122B1 (es) |
| JP (1) | JP5702853B2 (es) |
| KR (1) | KR101769079B1 (es) |
| CN (1) | CN102858159B (es) |
| AR (1) | AR081337A1 (es) |
| AU (1) | AU2011245393B2 (es) |
| BR (1) | BR112012026767B1 (es) |
| CA (1) | CA2795543C (es) |
| CL (1) | CL2012003009A1 (es) |
| CO (1) | CO6612267A2 (es) |
| CR (1) | CR20120557A (es) |
| CY (1) | CY1118187T1 (es) |
| DK (1) | DK2563122T3 (es) |
| DO (1) | DOP2012000263A (es) |
| EA (1) | EA021753B1 (es) |
| ES (1) | ES2588743T3 (es) |
| HK (1) | HK1175650A1 (es) |
| HR (1) | HRP20161103T1 (es) |
| HU (1) | HUE029480T2 (es) |
| IL (1) | IL222365A (es) |
| JO (1) | JO3131B1 (es) |
| LT (1) | LT2563122T (es) |
| MA (1) | MA34235B1 (es) |
| ME (1) | ME02490B (es) |
| MX (1) | MX2012012527A (es) |
| MY (1) | MY162933A (es) |
| NZ (1) | NZ602754A (es) |
| PE (1) | PE20130384A1 (es) |
| PL (1) | PL2563122T3 (es) |
| PT (1) | PT2563122T (es) |
| RS (1) | RS55079B1 (es) |
| SG (1) | SG184812A1 (es) |
| SI (1) | SI2563122T1 (es) |
| SM (1) | SMT201600293B (es) |
| UA (1) | UA110338C2 (es) |
| UY (1) | UY33353A (es) |
| WO (1) | WO2011137135A1 (es) |
| ZA (1) | ZA201207858B (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011326871B2 (en) | 2010-11-08 | 2015-02-12 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| KR20140067070A (ko) * | 2011-08-31 | 2014-06-03 | 말린크로트 엘엘씨 | Ｈ-포스포네이트에 의한 나노입자 ｐｅｇ 개질 |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| SG11201508469YA (en) | 2013-05-02 | 2015-11-27 | Glaxosmithkline Ip Dev Ltd | Therapeutic peptides |
| JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Ｅａファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| KR20170039195A (ko) * | 2014-08-05 | 2017-04-10 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 벤조티아제핀의 합성 |
| KR101674806B1 (ko) * | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| WO2016126721A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | 3-aryl-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
| US10183934B2 (en) | 2015-02-02 | 2019-01-22 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
| US11186558B2 (en) | 2016-06-27 | 2021-11-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Synthetic methods |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| ES2942443T3 (es) | 2018-06-05 | 2023-06-01 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| TWI823954B (zh) | 2018-06-20 | 2023-12-01 | 瑞典商艾爾比瑞歐公司 | 奧德維希百(odevixibat)之結晶修飾物 |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CA3127408A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| JP7504109B2 (ja) | 2019-02-06 | 2024-06-21 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| BR112021015809A2 (pt) * | 2019-02-12 | 2022-01-18 | Mirum Pharmaceuticals Inc | Resposta dependente de genótipo e dose a um asbti em pacientes com deficiência de bomba de exportação de sal biliar |
| WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| WO2021110886A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| TW202134222A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
| JP2023504643A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| MX2022006731A (es) * | 2019-12-04 | 2022-06-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar. |
| PT4069360T (pt) | 2019-12-04 | 2024-03-06 | Albireo Ab | Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar |
| JP2023504647A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| AR120682A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| EP4232043A1 (en) | 2020-10-20 | 2023-08-30 | GlaxoSmithKline Intellectual Property (No.2) Limited | Methods for treating cholestatic pruritus |
| KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
| CA3198216A1 (en) | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2022136335A1 (en) | 2020-12-23 | 2022-06-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Forms of linerixibat |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| AU2023255249A1 (en) | 2022-04-22 | 2024-10-17 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
| US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
| US20240067617A1 (en) | 2022-07-05 | 2024-02-29 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US20240207286A1 (en) | 2022-12-09 | 2024-06-27 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2370015A (en) | 1933-07-24 | 1945-02-20 | Merck & Co Inc | Derivatives of tertiary amino aliphatic acids |
| GB9203347D0 (en) * | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| ZA956647B (en) * | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| US6268392B1 (en) * | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| WO2002053548A1 (en) * | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Benzothiazepine derivatives |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20040077625A1 (en) * | 2001-07-25 | 2004-04-22 | Tremont Samuel J. | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| CA2471639A1 (en) * | 2002-01-17 | 2003-07-31 | Pharmacia Corporation | Novel alkyl/aryl hydroxy or keto thiepines. |
| NZ540895A (en) | 2003-01-09 | 2007-03-30 | Genentech Inc | Purification of polypeptides with ethacridine lactate |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| CA2583428A1 (en) | 2004-09-03 | 2006-03-09 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
| CN102316872B (zh) * | 2008-11-26 | 2016-12-21 | 萨蒂奥根制药公司 | 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂 |
-
2011
- 2011-04-25 JO JOP/2011/0139A patent/JO3131B1/ar active
- 2011-04-26 UY UY0001033353A patent/UY33353A/es not_active Application Discontinuation
- 2011-04-26 AR ARP110101432A patent/AR081337A1/es active IP Right Grant
- 2011-04-27 AU AU2011245393A patent/AU2011245393B2/en active Active
- 2011-04-27 MX MX2012012527A patent/MX2012012527A/es active IP Right Grant
- 2011-04-27 NZ NZ602754A patent/NZ602754A/en unknown
- 2011-04-27 ES ES11775513.2T patent/ES2588743T3/es active Active
- 2011-04-27 JP JP2013508174A patent/JP5702853B2/ja active Active
- 2011-04-27 LT LTEP11775513.2T patent/LT2563122T/lt unknown
- 2011-04-27 KR KR1020127030621A patent/KR101769079B1/ko active IP Right Grant
- 2011-04-27 WO PCT/US2011/034024 patent/WO2011137135A1/en active Application Filing
- 2011-04-27 CN CN201180021342.6A patent/CN102858159B/zh active Active
- 2011-04-27 EP EP11775513.2A patent/EP2563122B1/en active Active
- 2011-04-27 EA EA201290909A patent/EA021753B1/ru not_active IP Right Cessation
- 2011-04-27 PL PL11775513.2T patent/PL2563122T3/pl unknown
- 2011-04-27 MY MYPI2012004753A patent/MY162933A/en unknown
- 2011-04-27 RS RS20160709A patent/RS55079B1/sr unknown
- 2011-04-27 HU HUE11775513A patent/HUE029480T2/en unknown
- 2011-04-27 BR BR112012026767A patent/BR112012026767B1/pt active IP Right Grant
- 2011-04-27 ME MEP-2016-160A patent/ME02490B/me unknown
- 2011-04-27 CA CA2795543A patent/CA2795543C/en active Active
- 2011-04-27 US US13/640,166 patent/US9040518B2/en active Active
- 2011-04-27 PT PT117755132T patent/PT2563122T/pt unknown
- 2011-04-27 SG SG2012074860A patent/SG184812A1/en unknown
- 2011-04-27 DK DK11775513.2T patent/DK2563122T3/en active
- 2011-04-27 SI SI201130920A patent/SI2563122T1/sl unknown
- 2011-04-27 PE PE2012002082A patent/PE20130384A1/es active IP Right Grant
- 2011-04-27 MA MA35373A patent/MA34235B1/fr unknown
- 2011-04-27 UA UAA201211711A patent/UA110338C2/ru unknown
-
2012
- 2012-09-28 CO CO12170751A patent/CO6612267A2/es active IP Right Grant
- 2012-10-04 DO DO2012000263A patent/DOP2012000263A/es unknown
- 2012-10-11 IL IL222365A patent/IL222365A/en active IP Right Grant
- 2012-10-18 ZA ZA2012/07858A patent/ZA201207858B/en unknown
- 2012-10-26 CL CL2012003009A patent/CL2012003009A1/es unknown
- 2012-11-01 CR CR20120557A patent/CR20120557A/es unknown
-
2013
- 2013-03-07 HK HK13102840.3A patent/HK1175650A1/zh unknown
-
2016
- 2016-08-24 CY CY20161100830T patent/CY1118187T1/el unknown
- 2016-08-29 HR HRP20161103TT patent/HRP20161103T1/hr unknown
- 2016-08-29 SM SM201600293T patent/SMT201600293B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130384A1 (es) | Derivados de benzotiazepina | |
| PE20081545A1 (es) | Derivados de sulfonamida como inhibidores de acido graso sintasas | |
| PE20121182A1 (es) | Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina | |
| PE20131463A1 (es) | Piperidino-dihidrotienopirimidinas sustituidas | |
| PE20110136A1 (es) | Compuestos organicos | |
| PE20090328A1 (es) | Derivados de oxadiazol como moduladores de los receptores metabotropicos de glutamato | |
| PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20121010A1 (es) | Derivados de bencimidazol | |
| PE20091816A1 (es) | Inhibidores de bace | |
| WO2007125405A3 (en) | Substituted 2-amino-fused heterocyclic compounds | |
| ECSP066968A (es) | Compuestos de metil-aril o heteroaril-amida sustituida | |
| PE20070136A1 (es) | COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1 | |
| PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
| PE20081487A1 (es) | DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1 | |
| CL2011000394A1 (es) | Compuestos derivados de 1-hidroximetil-6,8-dioxa-biciclo[3.2.1]octano-2,3,4-triol, inhibidores de sglt2; cocristal que comprende a dicho compuesto y l-prolina o acido l-piroglutamico; composicion farmaceutica que los comprende; utiles para el tratamiento de la obesidad y diabetes de tipo 2. | |
| ATE552246T1 (de) | Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten | |
| CA2825172A1 (en) | Indole derivative and pharmacologically acceptable salt of same | |
| PE20060530A1 (es) | Aril y heteroaril derivados sustituidos como moduladores del metabolismo de la glucosa | |
| PE20110150A1 (es) | Amidofenoxiindazoles como inhibidores de c-met | |
| PE20090880A1 (es) | Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa | |
| CR20110013A (es) | Derivados de Heteroarilo como Inhibidores de DGAT1 | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| PE20130227A1 (es) | Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt | |
| PE20142282A1 (es) | Nuevos derivados de aril-quinolina | |
| PT2323972E (pt) | Compostos de tetraciclina substituídos com c7-flúor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |